COX-2 inhibitors obstructer the state of an enzyme that many tissues throughout the body utilize to make prostanoids, compounds that play a role in regulating an display of physiologic actions, such as inflaming, rip clotting, and shelter of the breadbasket application from the destructive effects of digestive acids.
Figure coxibs – celecoxib (Celebrex; Pfizer), rofecoxib (Vioxx), and valdecoxib (Bextra; Pfizer) – have been approved for use by the FDA ; a simple fraction, etoricoxib (Arcoxia, Merck), has been approved by the European regulatory expert and is currently under thinking for FDA acceptance, and a twenty percent, lumiracoxib (Prexige; Novartis), was recently approved in England and Mexico for the discourse of acute and chronic pain and is also under commercialism treatment by the FDA.
Other pain relievers, such as aspirin, ibuprofen, and naproxen, impediment not only COX-2 but also COX-1, a related enzyme.
COX-1 blocking plot leads to psychological state of the belly coating.
Therefore, the pinion selling taper that Merck emphasized in its mercantilism of Vioxx was the fact that it inhibits COX-2 and its painful inflammatory products while having no validity on COX-1, thereby producing fewer ulcers and other gastrointestinal problems.
This is a part of article Merck’s Withdrawal of Vioxx. Taken from "Generic Arcoxia (Etoricoxib)" Information Blog
No comments:
Post a Comment